Serina Therapeutics (SER) Gains from Investment Securities (2022 - 2025)

Serina Therapeutics has reported Gains from Investment Securities for 4 years, with the latest figure at -$3.2 million in Q4 2025.

• Quarterly Gains from Investment Securities fell 16.35% year-over-year to -$3.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$4.3 million (up 82.49% YoY) and the FY2025 annual result came in at -$4.3 million, up 67.32% from the prior year.
• Gains from Investment Securities eased to -$3.2 million in Q4 2025 per SER's latest filing, from -$1.0 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $956000.0 in Q2 2025 and troughed at -$9.3 million in Q2 2024.
• A 4-year average of -$1.8 million and a median of -$443500.0 in 2023 frame the typical range for Gains from Investment Securities.
• The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities tumbled 15294.44% in 2024, then jumped 110.28% in 2025.
• Over 4 years, Gains from Investment Securities stood at $5000.0 in 2022, then slumped by 460.0% to -$18000.0 in 2023, then sank by 15294.44% to -$2.8 million in 2024, then fell by 16.35% to -$3.2 million in 2025.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered -$3.2 million, -$1.0 million, and $956000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.